By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Cytokinetics, Inc. 

280 East Grand Avenue

South San Francisco  California  94080  U.S.A.
Phone: 650-624-3000 Fax: 650-624-3010


Drug Discovery

Company News
Cytokinetics (CYTK) Reports Fourth Quarter 2016 Financial Results 2/17/2017 8:38:44 AM
Cytokinetics (CYTK) To Announce Fourth Quarter Results On February 16, 2017 2/6/2017 8:00:53 AM
Cytokinetics (CYTK) Grabs a $100 Million Deal for Heart Drug With Royalty Pharma 2/2/2017 6:02:53 AM
Cytokinetics (CYTK) Announces New Data Presented At The International Symposium On ALS/MND 12/9/2016 6:25:13 AM
Origent And Cytokinetics (CYTK) Present Analyses Demonstrating Baseline Data Predict Measures Of Vital Capacity In Patients With ALS 12/7/2016 7:31:52 AM
Cytokinetics (CYTK) Announces Start Of GALACTIC-HF, A Phase III Clinical Trial Of Omecamtiv Mecarbil 12/1/2016 7:13:58 AM
Amgen (AMGN) And Cytokinetics (CYTK) Release: The Lancet Publishes Results From COSMIC-HF Trial Showing Omecamtiv Mecarbil Significantly Improved Cardiac Function In Patients With Chronic Heart Failure 12/1/2016 7:10:42 AM
Cytokinetics (CYTK) Announces Publication Relating To Novel Smooth Muscle Myosin Inhibitor 11/7/2016 7:40:24 AM
Cytokinetics (CYTK) Reports Third Quarter 2016 Financial Results 10/28/2016 7:54:09 AM
Cytokinetics (CYTK) Announces First Patient Enrolled In VIGOR-ALS, An Open-Label Extension Clinical Trial Of Tirasemtiv 10/18/2016 7:56:54 AM